Elanco Animal Health Incorporated (ELAN) Revenue History
Annual and quarterly revenue from 2016 to present
ELAN Revenue Over Time (2016–2025)
ELAN Revenue Growth History
7 of 9 years with positive growth- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- -0.8%
- FY2018 revenue growth
- +6.2%
- FY2019 revenue growth
- +0.1%
- FY2020 revenue growth
- +6.6%
- FY2021 revenue growth
- +45.5%
- FY2022 revenue growth
- -7.4%
- FY2023 revenue growth
- +0.1%
- FY2024 revenue growth
- +0.5%
- FY2025 revenue growth
- +6.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $1.37B | +14.9% |
| Q4 2025 | $1.14B | +12.2% |
| Q3 2025 | $1.14B | +10.4% |
| Q2 2025 | $1.24B | +4.8% |
| Q1 2025 | $1.19B | -1.0% |
| Q4 2024 | $1.02B | -1.4% |
| Q3 2024 | $1.03B | -3.6% |
| Q2 2024 | $1.18B | +12.0% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
ELAN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
ELAN Revenue Analysis (2016–2025)
Current Revenue & Growth
As of June 21, 2026, Elanco Animal Health Incorporated (ELAN) generated trailing twelve-month (TTM) revenue of $4.89 billion, reflecting strong growth of +14.9% year-over-year. The most recent quarter (Q1 2026) recorded $1.37 billion in revenue, up 19.8% sequentially.
Historical Growth Trajectory
ELAN's 5-year compound annual growth rate (CAGR) stands at +7.6%, indicating steady revenue expansion. The 3-year CAGR of +2.2% is below the 5-year average, signalling a growth deceleration in recent years. Elanco Animal Health Incorporated's highest annual revenue of $4.76 billion was recorded in 2021.
Revenue by Segment
ELAN's revenue is primarily driven by Farm Animal (33%), Pet Health (32%), and Cattle (16%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including ZTS (+2.4% YoY), PCRX (+4.6% YoY), and PAHC (+32.4% YoY) — ELAN has outperformed the peer group in revenue growth. Compare ELAN vs ZTS →
ELAN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ELANCurrent | $4.9B | +14.9% | +7.6% | 5.3% | |
 ZTS | $9.5B | +2.4% | +7.2% | 38.0% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 NEOG | $895M | -3.7% | +16.4% | 1.1% | |
 PETS | $179M | -21.1% | -10.0% | -17.5% |
ELAN Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.71B | +6.2% | $2.05B | 43.5% | $252.0M | 5.3% |
| 2024 | $4.44B | +0.5% | $1.91B | 43.0% | $251.0M | 5.7% |
| 2023 | $4.42B | +0.1% | $1.94B | 43.9% | $326.0M | 7.4% |
| 2022 | $4.41B | -7.4% | $1.97B | 44.7% | $384.0M | 8.7% |
| 2021 | $4.76B | +45.5% | $2.08B | 43.6% | $304.0M | 6.4% |
| 2020 | $3.27B | +6.6% | $1.25B | 38.1% | $-76,800,000 | -2.3% |
| 2019 | $3.07B | +0.1% | $1.40B | 45.6% | $370.0M | 12.0% |
| 2018 | $3.07B | +6.2% | $1.30B | 42.2% | $313.8M | 10.2% |
| 2017 | $2.89B | -0.8% | $1.17B | 40.6% | $142.4M | 4.9% |
| 2016 | $2.91B | - | $1.33B | 45.8% | $283.2M | 9.7% |
Full Stock Analysis
Deep dive into ELAN consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ELAN — Frequently Asked Questions
Quick answers to the most common questions about buying ELAN stock.
Is ELAN's revenue growth accelerating or slowing?
ELAN revenue growth is holding steady at +14.9% year-over-year. TTM revenue is $4.9B. The current growth rate closely tracks the 5-year CAGR of +7.6%, signalling consistent execution.
What is ELAN's revenue history from 2016 to 2026?
Elanco Animal Health Incorporated (ELAN) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $4.9B, growing at +14.9% YoY. The 5-year CAGR is +7.6%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ELAN's long-term revenue growth rate (CAGR)?
Elanco Animal Health Incorporated's 5-year revenue CAGR of +7.6% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +14.9% is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ELAN.
Why does ELAN's quarterly revenue fluctuate?
ELAN quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Elanco Animal Health Incorporated's revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is ELAN's revenue distributed by segment?
ELAN reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ELAN's revenue compare to industry peers?
Elanco Animal Health Incorporated (ELAN) with TTM revenue of $4.9B and +14.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.